capmatinib

Ligand id: 7904

Name: capmatinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 85.07
Molecular weight 412.14
XLogP 3.83
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Capmatinib is being assessed for various types of cancer either alone or in combination with other antineoplastics in many Phase 2 trials. Targeted indications include recurrent gliobastoma, advanced hepatocellular carcinoma, advanced non-small cell lung cancer, papillary renal cell cancer and advanced BRAF melanoma. For example capmatinib + nivolumab (an approved anti-PD-1 mAb) is being evaluated in study NCT02323126 (Phase 2 for previously treated NSCLC). NCT02795429 (Phase 1/2 in advanced HCC) is evaluating capmatinib + PDR001 (an investigational anti-PD-1 mAb). Click here to link to ClinicalTrials.gov's complete listing of Phase 2 capmatinib trials.